Skip to main content

Cancer Epigenetics – Haematological Malignancies

Cancer Epigenetics - Haematological Malignancies

Section Editors : Joost Martens

Associate Editors : Marcus Buschbeck, Saad Z Usmani

The section ‘Cancer Epigenetics- Hematological Malignancies’ aims to investigate the role of epigenetic mechanisms in the pathogenesis of hematological malignancies, welcoming submissions based both on translational research and clinical studies.

Despite the recent progresses in the understanding of the mechanisms of tumorigenesis of malignant hematopoietic cells, acute leukemias remain a disorder displaying poor survival rate; the mechanism(s) for relapse have still not been mechanistically clarified, as uncertain stays the role of the interplay between genome and epigenome deregulations in driving both the primary transformation and the possible relapse.

Studies targeting the role of epigenome deregulation underlying hematopoietic malignancies including the identification and characterization of the epi-landscape as a therapeutic target and/or studies of chromatin modulating drugs and clinical studies targeting epigenetics of hematopoietic malignancies are welcome.